PI
ZNTL icon

Pennant Investors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Pennant Investors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-32,400
Closed -$133K – 44
2024
Q2 		$133K Hold
32,400
– – 0.03% 43
2024
Q1 		$511K Hold
32,400
– – 0.13% 23
2023
Q4 		$491K Buy
+32,400
New +$473K 0.11% 22

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pennant Investors's ZNTL Position: Q3 2024 in Review

Pennant Investors sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 32,400 shares — an estimated $133K sold.

Pennant Investors first reported a position in ZNTL in Q4 2023 and held it in 3 quarters. The position peaked at $511K in Q1 2024. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Pennant Investors reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 32,400 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $133K.
  • Pennant Investors first reported a position in Zentalis Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Zentalis Pharmaceuticals position peaked at $511K in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.